Pharmaniaga Bhd
, one of Malaysia's largest integrated healthcare players, is well poised to take advantage of the vibrant growth in the pharmaceutical industry as well as the spillover effects from the growth in the biotech and medical tourism industries this year.
Given the group's bright prospects, analysts are recommending a “buy” on the stock with a 12-month target price of between RM5.95 and RM6.46 per share.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
